This company has no active jobs


Alchemia Limited is a listed Australian biopharmaceutical company (ASX:ACL) with an FDA approved drug (Fondaparinux sodium) and a late stage oncology product pipeline derived from the HyACT platform. In addition, Alchemia has a proprietary drug discovery platform, VAST®, derived from Alchemia’s chemistry expertise. Fondaparinux sodium - an FDA approved antithrombotic (a generic version of GlaxoSmithKline’s Arixtra®), targeting the multi-billion dollar heparin-drug market. Arixtra is a fully synthetic heparin fragment with superior safety characteristics over Lovenox (low molecular weight heparin). Alchemia has partnered this product with Dr Reddy’s and received its first profits from sales of fondaparinux in August 2011. Alchemia's fondaparinux market share by volume has risen to secure over 30% across all sectors, securing approximately 50% of the more profitable retail market. Alchemia Oncology Inc. is a wholly owned subsidiary of Alchemia Limited and was established to commercialise its HyACT and VAST platforms including HA-Irinotecan, Alchemia’s Phase III product for mCRC.
  • Company Phone 03 9692 7222
  • Address Line 1 c/- Level 4, 100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA,
  • City Melbourne
  • State Victoria
  • Country Australia
  • Postcode 3205
  • Industry Pharmaceuticals, Biotechnology & Life Sciences
Connect with us

Hi! How can we help you?

Click below button to start chat

Chat Icon
chat icon